Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Bluebird Bio (NASDAQ: BLUE) yesterday. The company’s shares closed yesterday at $132.69.
According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 2.6% and a 37.3% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Pieris Pharmaceuticals, and Nektar Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bluebird Bio with a $204.40 average price target, representing a 54.0% upside. In a report issued on November 1, William Blair also assigned a Buy rating to the stock.
See today’s analyst top recommended stocks >>
Based on Bluebird Bio’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $146 million. In comparison, last year the company had a GAAP net loss of $78.81 million.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLUE in relation to earlier this year. Most recently, in August 2018, Jason Cole, the CLO of BLUE bought 4,438 shares for a total of $99,988.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. It offers the LentiGlobin which is a treatment for transfusion-dependent ß-thalassemia; and Lenti-D as a treatment for cerebral adrenoleukodystrophy.